Clinical trial
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
NCT06790420 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2025
- Completion date
- March 14, 2025
- Enrollment
- 2,703 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.